{"transactions":[{"id":673027,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":18743,"kind":"person","name":"Vandekop Amy O'Leary","position":1,"cik":"0002146984","reported_name":"Vandekop Amy O'Leary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Corporate Controller"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-28T16:10:50.000Z","date":"2026-08-27","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":10000,"derivative":{"exercise_price":4.1,"expiration_date":"2036-08-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-374352","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526374352/ownership.xml","form_type":"4"}},{"id":698941,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":27196,"kind":"person","name":"KEATING LAURIE","position":1,"cik":"0001620743","reported_name":"KEATING LAURIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:05:12.000Z","date":"2026-08-01","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":3.51,"expiration_date":"2036-07-31","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001193125-26-330530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526330530/ownership.xml","form_type":"4"}},{"id":705809,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":29532,"kind":"person","name":"Bayko Liisa Ann","position":1,"cik":"0002145720","reported_name":"Bayko Liisa Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-20T21:04:40.000Z","date":"2026-07-20","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 20, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on July 20, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":220000,"derivative":{"exercise_price":4,"expiration_date":"2036-07-19","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001193125-26-309047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526309047/ownership.xml","form_type":"4"}},{"id":749664,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:38:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257564/ownership.xml","form_type":"4"}},{"id":749663,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41363,"kind":"person","name":"Ferrara Napoleone","position":1,"cik":"0001744779","reported_name":"Ferrara Napoleone","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:36:07.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257556","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257556/ownership.xml","form_type":"4"}},{"id":749662,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:28:52.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257494/ownership.xml","form_type":"4"}},{"id":749661,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:25:17.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257471/ownership.xml","form_type":"4"}},{"id":749660,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":39163,"kind":"person","name":"Dybbs Michael","position":1,"cik":"0001601264","reported_name":"Dybbs Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:23:12.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257465/ownership.xml","form_type":"4"}},{"id":749659,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41361,"kind":"person","name":"ADAMIS ANTHONY P","position":1,"cik":"0001277479","reported_name":"ADAMIS ANTHONY P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:22:41.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257462","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257462/ownership.xml","form_type":"4"}},{"id":749658,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":39209,"kind":"person","name":"PATTERSON LEONE D","position":1,"cik":"0001233539","reported_name":"PATTERSON LEONE D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:19:18.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257445/ownership.xml","form_type":"4"}},{"id":766025,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":3,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44748,"kind":"organization","name":"Samsara Opportunity Fund, L.P.","position":4,"cik":"0002086193","reported_name":"Samsara Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44749,"kind":"organization","name":"Samsara Opportunity Fund GP, LLC","position":5,"cik":"0002086456","reported_name":"Samsara Opportunity Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T23:47:34.000Z","date":"2026-05-20","kind":"other","planned":false,"acquired":true,"shares":4471,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Samsara BioCapital Partners, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents receipt of shares in the distribution in kind described in footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":19408,"source":{"system":"sec-edgar","filing":"0001231919-26-000532","document":"form4-05222026_110527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000123191926000532/form4-05222026_110527.xml","form_type":"4"}},{"id":766024,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":3,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44748,"kind":"organization","name":"Samsara Opportunity Fund, L.P.","position":4,"cik":"0002086193","reported_name":"Samsara Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44749,"kind":"organization","name":"Samsara Opportunity Fund GP, LLC","position":5,"cik":"0002086456","reported_name":"Samsara Opportunity Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T23:47:34.000Z","date":"2026-05-20","kind":"other","planned":false,"acquired":true,"shares":14937,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Samsara BioCapital GP, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Represents receipt of shares in the distribution in kind described in footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":14937,"source":{"system":"sec-edgar","filing":"0001231919-26-000532","document":"form4-05222026_110527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000123191926000532/form4-05222026_110527.xml","form_type":"4"}},{"id":766023,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":3,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44748,"kind":"organization","name":"Samsara Opportunity Fund, L.P.","position":4,"cik":"0002086193","reported_name":"Samsara Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44749,"kind":"organization","name":"Samsara Opportunity Fund GP, LLC","position":5,"cik":"0002086456","reported_name":"Samsara Opportunity Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T23:47:34.000Z","date":"2026-05-20","kind":"other","planned":false,"acquired":false,"shares":66906,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP.  Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC (\"Samsara LLC\"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. (\"Samsara BioCapital Partners\"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The shares held by Samsara LP reflects the disposition of 244,300\nshares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":10657028,"source":{"system":"sec-edgar","filing":"0001231919-26-000532","document":"form4-05222026_110527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000123191926000532/form4-05222026_110527.xml","form_type":"4"}},{"id":766022,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":3,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44748,"kind":"organization","name":"Samsara Opportunity Fund, L.P.","position":4,"cik":"0002086193","reported_name":"Samsara Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44749,"kind":"organization","name":"Samsara Opportunity Fund GP, LLC","position":5,"cik":"0002086456","reported_name":"Samsara Opportunity Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T23:47:34.000Z","date":"2026-05-20","kind":"purchase","planned":false,"acquired":true,"shares":244300,"price":4.83,"value":1179969.0,"ownership":{"direct":false,"nature":"By Samsara Opportunity Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the purchase of shares from Samsara BioCapital, L.P. (\"Samsara LP\") in a privately negotiated transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are directly held by Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\"). Samsara Opportunity Fund GP, LLC (\"Samsara Opportunity GP\") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein."}],"balance_after":2224147,"source":{"system":"sec-edgar","filing":"0001231919-26-000532","document":"form4-05222026_110527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000123191926000532/form4-05222026_110527.xml","form_type":"4"}},{"id":830823,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-23T20:05:11.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":60800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":60800,"derivative":{"exercise_price":6.81,"expiration_date":"2036-03-18","underlying":"Common Stock","underlying_shares":60800},"source":{"system":"sec-edgar","filing":"0001193125-26-119707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526119707/ownership.xml","form_type":"4"}},{"id":830822,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-23T20:05:11.000Z","date":"2026-03-20","kind":"sale","planned":false,"acquired":false,"shares":1915,"price":6.72,"value":12868.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Due to an administrative error, the Reporting Person filed a Form 4 on March 27, 2025 reporting beneficial ownership of 1,925 shares, when in fact the amount of securities beneficially owned was 1,915. The number of shares beneficially owned by the Reporting Person following the transaction reported herein has been updated accordingly."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-119707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526119707/ownership.xml","form_type":"4"}},{"id":832395,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:05:07.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":222000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":222000,"derivative":{"exercise_price":6.81,"expiration_date":"2036-03-18","underlying":"Common Stock","underlying_shares":222000},"source":{"system":"sec-edgar","filing":"0001193125-26-117618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526117618/ownership.xml","form_type":"4"}},{"id":832418,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":49667,"kind":"person","name":"Gall Matthew","position":1,"cik":"0001816194","reported_name":"Gall Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:05:05.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":95000,"derivative":{"exercise_price":6.81,"expiration_date":"2036-03-18","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001193125-26-117617","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816194/000119312526117617/ownership.xml","form_type":"4"}},{"id":832393,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56839,"kind":"person","name":"Feinsod Matthew","position":1,"cik":"0001716950","reported_name":"Feinsod Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:05:04.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":135000,"derivative":{"exercise_price":6.81,"expiration_date":"2036-03-18","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001193125-26-117616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526117616/ownership.xml","form_type":"4"}},{"id":901136,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":3,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44748,"kind":"organization","name":"Samsara Opportunity Fund, L.P.","position":4,"cik":"0002086193","reported_name":"Samsara Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44749,"kind":"organization","name":"Samsara Opportunity Fund GP, LLC","position":5,"cik":"0002086456","reported_name":"Samsara Opportunity Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-18T01:15:32.000Z","date":"2025-12-18","kind":"purchase","planned":false,"acquired":true,"shares":479847,"price":10.42,"value":5000005.74,"ownership":{"direct":false,"nature":"By Samsara Opportunity Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the purchase of shares from Samsara BioCapital, L.P. (\"Samsara LP\") in a privately negotiated transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the \"Prior Report\").  The Prior Report is deemed amended hereby."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC (\"Samsara Opportunity GP\") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein."}],"balance_after":1979847,"source":{"system":"sec-edgar","filing":"0001231919-26-000166","document":"form4-02182026_010226.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000123191926000166/form4-02182026_010226.xml","form_type":"4"}},{"id":961036,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44748,"kind":"organization","name":"Samsara Opportunity Fund, L.P.","position":2,"cik":"0002086193","reported_name":"Samsara Opportunity Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44749,"kind":"organization","name":"Samsara Opportunity Fund GP, LLC","position":3,"cik":"0002086456","reported_name":"Samsara Opportunity Fund GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T21:15:40.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":1500000,"price":10,"value":15000000.0,"ownership":{"direct":false,"nature":"By Samsara Opportunity Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are directly held by Samsara Opportunity Fund, L.P. (\"Samsara Opportunity Fund\"). Samsara Opportunity Fund GP, LLC (\"Samsara Opportunity GP\") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Samsara Opportunity GP and Dr. Akkaraju have voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of his or its respective pecuniary interest therein."}],"balance_after":1500000,"source":{"system":"sec-edgar","filing":"0001231919-25-000652","document":"form4-12222025_091234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000123191925000652/form4-12222025_091234.xml","form_type":"4"}},{"id":1009648,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":49667,"kind":"person","name":"Gall Matthew","position":1,"cik":"0001816194","reported_name":"Gall Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-03T22:25:05.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":235000,"derivative":{"exercise_price":4.99,"expiration_date":"2035-11-02","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001193125-25-262831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816194/000119312525262831/ownership.xml","form_type":"4"}},{"id":1173322,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T21:27:32.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":50262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":50262,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":50262},"source":{"system":"sec-edgar","filing":"0000950170-25-053382","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053382/ownership.xml","form_type":"4"}},{"id":1173319,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T21:20:13.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053379","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053379/ownership.xml","form_type":"4"}},{"id":1173323,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T21:08:35.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053372","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053372/ownership.xml","form_type":"4"}},{"id":1173320,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":80857,"kind":"person","name":"PATEL SAMIR CHANDRAKANT","position":1,"cik":"0001277966","reported_name":"PATEL SAMIR CHANDRAKANT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T21:04:19.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053369","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053369/ownership.xml","form_type":"4"}},{"id":1173317,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41363,"kind":"person","name":"Ferrara Napoleone","position":1,"cik":"0001744779","reported_name":"Ferrara Napoleone","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T21:03:27.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053368","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053368/ownership.xml","form_type":"4"}},{"id":1173318,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":39163,"kind":"person","name":"Dybbs Michael","position":1,"cik":"0001601264","reported_name":"Dybbs Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:59:26.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053358","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053358/ownership.xml","form_type":"4"}},{"id":1173316,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:55:49.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":287000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":287000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":287000},"source":{"system":"sec-edgar","filing":"0000950170-25-053347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053347/ownership.xml","form_type":"4"}},{"id":1173321,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41361,"kind":"person","name":"ADAMIS ANTHONY P","position":1,"cik":"0001277479","reported_name":"ADAMIS ANTHONY P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:52:28.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053339","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053339/ownership.xml","form_type":"4"}},{"id":1173315,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56839,"kind":"person","name":"Feinsod Matthew","position":1,"cik":"0001716950","reported_name":"Feinsod Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:52:08.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":101000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":101000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":101000},"source":{"system":"sec-edgar","filing":"0000950170-25-053338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053338/ownership.xml","form_type":"4"}},{"id":1173314,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56839,"kind":"person","name":"Feinsod Matthew","position":1,"cik":"0001716950","reported_name":"Feinsod Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:52:08.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":70551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on December 31, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":70551,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":70551},"source":{"system":"sec-edgar","filing":"0000950170-25-053338","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053338/ownership.xml","form_type":"4"}},{"id":1173313,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":39209,"kind":"person","name":"PATTERSON LEONE D","position":1,"cik":"0001233539","reported_name":"PATTERSON LEONE D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:48:34.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from April 3, 2025 through April 3, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053330","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053330/ownership.xml","form_type":"4"}},{"id":1173311,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:41:02.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053318/ownership.xml","form_type":"4"}},{"id":1189877,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-03-27T23:19:58.000Z","date":"2025-03-26","kind":"sale","planned":false,"acquired":false,"shares":907,"price":8.9693,"value":8135.1551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.70 to $9.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2)."}],"balance_after":1925,"source":{"system":"sec-edgar","filing":"0000950170-25-046263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025046263/ownership.xml","form_type":"4"}},{"id":1200007,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41363,"kind":"person","name":"Ferrara Napoleone","position":1,"cik":"0001744779","reported_name":"Ferrara Napoleone","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-18T21:45:09.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":504000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the Merger)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer."}],"balance_after":504000,"source":{"system":"sec-edgar","filing":"0000950170-25-041498","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041498/ownership.xml","form_type":"4"}},{"id":1200006,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":80857,"kind":"person","name":"PATEL SAMIR CHANDRAKANT","position":1,"cik":"0001277966","reported_name":"PATEL SAMIR CHANDRAKANT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-18T21:44:51.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":105913,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"Stock option assumed in connection with the closing of the Merger, in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the \"Exchange Ratio\") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests over four years beginning on the vesting commencement date of October 1, 2023, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":105913,"derivative":{"exercise_price":0.85,"expiration_date":"2034-05-27","underlying":"Common Stock","underlying_shares":105913},"source":{"system":"sec-edgar","filing":"0000950170-25-041496","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041496/ownership.xml","form_type":"4"}},{"id":1200005,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":80857,"kind":"person","name":"PATEL SAMIR CHANDRAKANT","position":1,"cik":"0001277966","reported_name":"PATEL SAMIR CHANDRAKANT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-18T21:44:51.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":100800,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such, transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the \"Exchange Ratio\") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by S&S New Hampshire Trust (the \"S&S Shares\") for the benefit of the reporting person's children. The reporting person may be deemed to have beneficial ownership over the S&S Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":100800,"source":{"system":"sec-edgar","filing":"0000950170-25-041496","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041496/ownership.xml","form_type":"4"}},{"id":1200004,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":80857,"kind":"person","name":"PATEL SAMIR CHANDRAKANT","position":1,"cik":"0001277966","reported_name":"PATEL SAMIR CHANDRAKANT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-18T21:44:51.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":252000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such, transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the \"Exchange Ratio\") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."}],"balance_after":252000,"source":{"system":"sec-edgar","filing":"0000950170-25-041496","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041496/ownership.xml","form_type":"4"}},{"id":1200003,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56839,"kind":"person","name":"Feinsod Matthew","position":1,"cik":"0001716950","reported_name":"Feinsod Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-18T21:43:41.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":28224,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"Stock option assumed in connection with the closing of the Merger, in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the \"Exchange Ratio\") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests over four years beginning on the vesting commencement date of June 17, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":28224,"derivative":{"exercise_price":0.85,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":28224},"source":{"system":"sec-edgar","filing":"0000950170-25-041494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041494/ownership.xml","form_type":"4"}},{"id":1200002,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56839,"kind":"person","name":"Feinsod Matthew","position":1,"cik":"0001716950","reported_name":"Feinsod Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-18T21:43:41.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":4030,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the \"Exchange Ratio\") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."}],"balance_after":4030,"source":{"system":"sec-edgar","filing":"0000950170-25-041494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041494/ownership.xml","form_type":"4"}},{"id":1200001,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-18T21:41:07.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":476611,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests over four years beginning on the vesting commencement date of March 4, 2024, with 25% of the shares underlying the option having vested on March 4, 2025, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":476611,"derivative":{"exercise_price":0.85,"expiration_date":"2034-05-27","underlying":"Common Stock","underlying_shares":476611},"source":{"system":"sec-edgar","filing":"0000950170-25-041485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041485/ownership.xml","form_type":"4"}},{"id":1200000,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":1,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-18T21:40:57.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":11444503,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by Samsara BioCapital, L.P. (\"Samsara LP\"). Samsara BioCapital GP, LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein."}],"balance_after":11444503,"source":{"system":"sec-edgar","filing":"0000950170-25-041484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041484/ownership.xml","form_type":"4"}},{"id":1199999,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41361,"kind":"person","name":"ADAMIS ANTHONY P","position":1,"cik":"0001277479","reported_name":"ADAMIS ANTHONY P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-18T21:37:53.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":12989,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, as the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests over four years beginning on the vesting commencement date of October 1, 2021, with 25% of the shares underlying the option having vested on October 1, 2022, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":12989,"derivative":{"exercise_price":0.55,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":12989},"source":{"system":"sec-edgar","filing":"0000950170-25-041475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041475/ownership.xml","form_type":"4"}},{"id":1199998,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41361,"kind":"person","name":"ADAMIS ANTHONY P","position":1,"cik":"0001277479","reported_name":"ADAMIS ANTHONY P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-18T21:37:53.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":19484,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, as the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests over four years beginning on the vesting commencement date of October 1, 2021, with 25% of the shares underlying the option having vested on October 1, 2022, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":19484,"derivative":{"exercise_price":0.55,"expiration_date":"2032-07-25","underlying":"Common Stock","underlying_shares":19484},"source":{"system":"sec-edgar","filing":"0000950170-25-041475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041475/ownership.xml","form_type":"4"}},{"id":1249708,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-24T21:15:10.000Z","date":"2025-02-21","kind":"sale","planned":false,"acquired":false,"shares":303,"price":10.0758,"value":3052.9674,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":49129,"source":{"system":"sec-edgar","filing":"0000950170-25-025634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025025634/ownership.xml","form_type":"4"}},{"id":1249707,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-24T21:15:08.000Z","date":"2025-02-21","kind":"sale","planned":false,"acquired":false,"shares":96,"price":10.0758,"value":967.2768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2832,"source":{"system":"sec-edgar","filing":"0000950170-25-025633","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025025633/ownership.xml","form_type":"4"}},{"id":1249706,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-02-24T21:15:05.000Z","date":"2025-02-21","kind":"sale","planned":false,"acquired":false,"shares":106,"price":10.0758,"value":1068.0348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":6517,"source":{"system":"sec-edgar","filing":"0000950170-25-025630","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025025630/ownership.xml","form_type":"4"}},{"id":1294528,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-27T21:16:31.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":5,"price":9.9402,"value":49.701,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":6623,"source":{"system":"sec-edgar","filing":"0000950170-25-009205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009205/ownership.xml","form_type":"4"}},{"id":1294527,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-27T21:16:31.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":47,"price":9.4538,"value":444.3286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":6628,"source":{"system":"sec-edgar","filing":"0000950170-25-009205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009205/ownership.xml","form_type":"4"}},{"id":1294526,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-27T21:15:17.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":4,"price":9.9402,"value":39.7608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":2928,"source":{"system":"sec-edgar","filing":"0000950170-25-009204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009204/ownership.xml","form_type":"4"}},{"id":1294525,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-27T21:15:17.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":32,"price":9.4538,"value":302.5216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":2932,"source":{"system":"sec-edgar","filing":"0000950170-25-009204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009204/ownership.xml","form_type":"4"}},{"id":1294522,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-27T21:11:26.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":13,"price":9.9402,"value":129.2226,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":49432,"source":{"system":"sec-edgar","filing":"0000950170-25-009197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009197/ownership.xml","form_type":"4"}},{"id":1294521,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-27T21:11:26.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":116,"price":9.4538,"value":1096.6408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":49445,"source":{"system":"sec-edgar","filing":"0000950170-25-009197","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009197/ownership.xml","form_type":"4"}},{"id":1304350,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-13T21:15:08.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":409,"price":0.4401,"value":180.0009,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":153541,"source":{"system":"sec-edgar","filing":"0000950170-25-004834","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025004834/ownership.xml","form_type":"4"}},{"id":1304349,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-13T21:15:06.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":332,"price":0.4401,"value":146.1132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":68174,"source":{"system":"sec-edgar","filing":"0000950170-25-004833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025004833/ownership.xml","form_type":"4"}},{"id":1304348,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-01-13T21:15:05.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":979,"price":0.4401,"value":430.8579,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1139915,"source":{"system":"sec-edgar","filing":"0000950170-25-004832","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025004832/ownership.xml","form_type":"4"}},{"id":1335751,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-12-11T22:07:44.000Z","date":"2024-12-11","kind":"gift","planned":false,"acquired":true,"shares":57549,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 11, 2024, the Reporting Person transferred 57,549 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":346348,"source":{"system":"sec-edgar","filing":"0000950170-24-135443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024135443/ownership.xml","form_type":"4"}},{"id":1335750,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-12-11T22:07:44.000Z","date":"2024-12-11","kind":"gift","planned":false,"acquired":false,"shares":57549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 11, 2024, the Reporting Person transferred 57,549 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":153950,"source":{"system":"sec-edgar","filing":"0000950170-24-135443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024135443/ownership.xml","form_type":"4"}},{"id":1357310,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-11-20T21:15:11.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":554,"price":0.5485,"value":303.869,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":68506,"source":{"system":"sec-edgar","filing":"0000950170-24-129263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024129263/ownership.xml","form_type":"4"}},{"id":1357309,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-11-20T21:15:06.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":3186,"price":0.5485,"value":1747.521,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1140894,"source":{"system":"sec-edgar","filing":"0000950170-24-129259","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024129259/ownership.xml","form_type":"4"}},{"id":1357308,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-11-20T21:15:05.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":432,"price":0.5485,"value":236.952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":211499,"source":{"system":"sec-edgar","filing":"0000950170-24-129258","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024129258/ownership.xml","form_type":"4"}},{"id":1357347,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-20T16:15:03.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":8706,"price":0.5485,"value":4775.241,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":723363,"source":{"system":"sec-edgar","filing":"0000950170-24-129257","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024129257/ownership.xml","form_type":"4"}},{"id":1374289,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-11-06T21:15:12.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":2272,"price":0.8649,"value":1965.0528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":211931,"source":{"system":"sec-edgar","filing":"0000950170-24-122335","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024122335/ownership.xml","form_type":"4"}},{"id":1374288,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-11-06T21:15:11.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":1655,"price":0.8649,"value":1431.4095,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":69060,"source":{"system":"sec-edgar","filing":"0000950170-24-122334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024122334/ownership.xml","form_type":"4"}},{"id":1374290,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-11-06T21:15:09.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":5136,"price":0.8649,"value":4442.1264,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1144080,"source":{"system":"sec-edgar","filing":"0000950170-24-122333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024122333/ownership.xml","form_type":"4"}},{"id":1374333,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-06T16:15:14.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":10609,"price":0.8649,"value":9175.7241,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":732069,"source":{"system":"sec-edgar","filing":"0000950170-24-122336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024122336/ownership.xml","form_type":"4"}},{"id":1382397,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:04.000Z","date":"2024-10-22","kind":"sale","planned":false,"acquired":false,"shares":1882,"price":0.7678,"value":1444.9996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1149216,"source":{"system":"sec-edgar","filing":"0000950170-24-116648","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116648/ownership.xml","form_type":"4"}},{"id":1382396,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:04.000Z","date":"2024-10-21","kind":"sale","planned":false,"acquired":false,"shares":1546,"price":0.779,"value":1204.334,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1151098,"source":{"system":"sec-edgar","filing":"0000950170-24-116648","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116648/ownership.xml","form_type":"4"}},{"id":1382395,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:03.000Z","date":"2024-10-22","kind":"sale","planned":false,"acquired":false,"shares":486,"price":0.7678,"value":373.1508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":70715,"source":{"system":"sec-edgar","filing":"0000950170-24-116646","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116646/ownership.xml","form_type":"4"}},{"id":1382394,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:03.000Z","date":"2024-10-21","kind":"sale","planned":false,"acquired":false,"shares":479,"price":0.779,"value":373.141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":71201,"source":{"system":"sec-edgar","filing":"0000950170-24-116646","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116646/ownership.xml","form_type":"4"}},{"id":1382393,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:02.000Z","date":"2024-10-22","kind":"sale","planned":false,"acquired":false,"shares":766,"price":0.7678,"value":588.1348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":214203,"source":{"system":"sec-edgar","filing":"0000950170-24-116644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116644/ownership.xml","form_type":"4"}},{"id":1382392,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:02.000Z","date":"2024-10-21","kind":"sale","planned":false,"acquired":false,"shares":635,"price":0.779,"value":494.665,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":214969,"source":{"system":"sec-edgar","filing":"0000950170-24-116644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116644/ownership.xml","form_type":"4"}},{"id":1382399,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-23T16:15:04.000Z","date":"2024-10-21","kind":"sale","planned":false,"acquired":false,"shares":9752,"price":0.779,"value":7596.808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":742678,"source":{"system":"sec-edgar","filing":"0000950170-24-116645","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024116645/ownership.xml","form_type":"4"}},{"id":1390805,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-10-04T20:15:07.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":940,"price":0.8148,"value":765.912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":1152644,"source":{"system":"sec-edgar","filing":"0000950170-24-112914","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024112914/ownership.xml","form_type":"4"}},{"id":1390804,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-10-04T20:15:06.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":377,"price":0.8148,"value":307.1796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":215604,"source":{"system":"sec-edgar","filing":"0000950170-24-112913","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024112913/ownership.xml","form_type":"4"}},{"id":1390803,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-10-04T20:15:03.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":301,"price":0.8148,"value":245.2548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":71680,"source":{"system":"sec-edgar","filing":"0000950170-24-112911","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024112911/ownership.xml","form_type":"4"}},{"id":1390830,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-10-04T16:15:04.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":1493,"price":0.8148,"value":1216.4964,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":752430,"source":{"system":"sec-edgar","filing":"0000950170-24-112912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024112912/ownership.xml","form_type":"4"}},{"id":1425464,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-22T16:15:03.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":5390,"price":0.7413,"value":3995.607,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7384 to $0.745. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":753923,"source":{"system":"sec-edgar","filing":"0000950170-24-099846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024099846/ownership.xml","form_type":"4"}},{"id":1427714,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-20T20:15:05.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":422,"price":0.7595,"value":320.509,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":215981,"source":{"system":"sec-edgar","filing":"0000950170-24-099106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024099106/ownership.xml","form_type":"4"}},{"id":1427713,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-08-20T20:15:03.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":544,"price":0.7595,"value":413.168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":71981,"source":{"system":"sec-edgar","filing":"0000950170-24-099104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024099104/ownership.xml","form_type":"4"}},{"id":1427712,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-20T20:15:03.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":3159,"price":0.7595,"value":2399.2605,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1153584,"source":{"system":"sec-edgar","filing":"0000950170-24-099103","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024099103/ownership.xml","form_type":"4"}},{"id":1427791,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-20T16:15:02.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":3091,"price":0.7595,"value":2347.6145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":759313,"source":{"system":"sec-edgar","filing":"0000950170-24-099102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024099102/ownership.xml","form_type":"4"}},{"id":1438843,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-07T20:15:06.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":2323,"price":0.7348,"value":1706.9404,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":216403,"source":{"system":"sec-edgar","filing":"0000950170-24-092808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024092808/ownership.xml","form_type":"4"}},{"id":1438842,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-07T20:15:03.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":5251,"price":0.7348,"value":3858.4348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1156743,"source":{"system":"sec-edgar","filing":"0000950170-24-092809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024092809/ownership.xml","form_type":"4"}},{"id":1438840,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-08-07T20:15:03.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":1692,"price":0.7348,"value":1243.2816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":72525,"source":{"system":"sec-edgar","filing":"0000950170-24-092806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024092806/ownership.xml","form_type":"4"}},{"id":1438865,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-08-07T16:15:04.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":10847,"price":0.7348,"value":7970.3756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":762404,"source":{"system":"sec-edgar","filing":"0000950170-24-092807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024092807/ownership.xml","form_type":"4"}},{"id":1449965,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-07-23T20:28:40.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":481,"price":0.7392,"value":355.5552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":74217,"source":{"system":"sec-edgar","filing":"0000950170-24-085670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085670/ownership.xml","form_type":"4"}},{"id":1449964,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-07-23T20:28:40.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":479,"price":0.7501,"value":359.2979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":74698,"source":{"system":"sec-edgar","filing":"0000950170-24-085670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085670/ownership.xml","form_type":"4"}},{"id":1449962,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-07-23T20:27:24.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":1858,"price":0.7392,"value":1373.4336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1161994,"source":{"system":"sec-edgar","filing":"0000950170-24-085663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085663/ownership.xml","form_type":"4"}},{"id":1449961,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-07-23T20:27:24.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":1542,"price":0.7501,"value":1156.6542,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1163852,"source":{"system":"sec-edgar","filing":"0000950170-24-085663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085663/ownership.xml","form_type":"4"}},{"id":1449960,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-07-23T20:25:37.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":757,"price":0.7392,"value":559.5744,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":218726,"source":{"system":"sec-edgar","filing":"0000950170-24-085658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085658/ownership.xml","form_type":"4"}},{"id":1449959,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-07-23T20:25:37.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":634,"price":0.7501,"value":475.5634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":219483,"source":{"system":"sec-edgar","filing":"0000950170-24-085658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085658/ownership.xml","form_type":"4"}},{"id":1449983,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-23T16:28:25.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":9731,"price":0.7501,"value":7299.2231,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":773251,"source":{"system":"sec-edgar","filing":"0000950170-24-085669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024085669/ownership.xml","form_type":"4"}},{"id":1460126,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-07-03T20:14:49.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":379,"price":0.72,"value":272.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":220117,"source":{"system":"sec-edgar","filing":"0000950170-24-081519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024081519/ownership.xml","form_type":"4"}},{"id":1460125,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":51945,"kind":"person","name":"Sinha Vikas","position":1,"cik":"0001337845","reported_name":"Sinha Vikas","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-07-03T20:14:43.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":939,"price":0.72,"value":676.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 36,337 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 28, 2024."}],"balance_after":1165394,"source":{"system":"sec-edgar","filing":"0000950170-24-081518","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024081518/ownership.xml","form_type":"4"}},{"id":1460124,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-07-03T20:12:53.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":304,"price":0.72,"value":218.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":75177,"source":{"system":"sec-edgar","filing":"0000950170-24-081515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024081515/ownership.xml","form_type":"4"}},{"id":1460198,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":74782,"kind":"person","name":"Brainard Diana","position":1,"cik":"0001818070","reported_name":"Brainard Diana","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-07-03T16:11:17.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":1489,"price":0.72,"value":1072.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":782982,"source":{"system":"sec-edgar","filing":"0000950170-24-081511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818070/000095017024081511/ownership.xml","form_type":"4"}},{"id":1486928,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:05:15.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":100197,"source":{"system":"sec-edgar","filing":"0000950170-24-070602","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024070602/ownership.xml","form_type":"4"}},{"id":1486927,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41362,"kind":"person","name":"Hallal David","position":1,"cik":"0001457477","reported_name":"Hallal David","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:05:13.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":2143662,"source":{"system":"sec-edgar","filing":"0000950170-24-070600","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024070600/ownership.xml","form_type":"4"}}],"next_cursor":"2024-06-07T20:05:13.000000Z,1486927"}